Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831358 | 0.92 | NR1I2 (0.54) | LMNANR1I2PGRALDH1A1 | |
| SCHEMBL2834863 | 0.89 | LMNA (0.47) | LMNANR1I2PGRALDH1A1TDP1 | |
| SCHEMBL2832988 | 0.82 | LMNA (0.55) | LMNANR1I2PGRALDH1A1TDP1 | |
| SCHEMBL2837930 | 0.82 | LMNA (0.41) | LMNANR1I2PGRALDH1A1TDP1 | |
| SCHEMBL2837914 | 0.82 | LMNA (0.55) | LMNANR1I2PGRALDH1A1TDP1 | |
| SCHEMBL2833656 | 0.81 | NR1I2 (0.66) | LMNANR1I2PGRALDH1A1MAPT | |
| SCHEMBL29885271 | 0.79 | ALDH1A1 (0.35) | LMNANR1I2PGRALDH1A1TDP1 | |
| SCHEMBL2838626 | 0.79 | NR1I2 (0.62) | LMNANR1I2PGRALDH1A1MAPT | |
| SCHEMBL2832404 | 0.79 | NR1I2 (0.62) | LMNANR1I2PGRALDH1A1MAPT | |
| SCHEMBL2835821 | 0.79 | NR1I2 (0.62) | LMNANR1I2PGRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866323-B1 | GLUCURONIDATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1848424-B1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2808015-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-17 | — | — | US | disclosed |
| US-7838552-B2 | Compositions comprising nebivolol | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-23 | — | — | US | disclosed |
| EP-2174658-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-1982711-A1 | Compositions comprsing nebivolol | MYLAN LABORATORIES, INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080161296-A1 | Compositions comprising nebivolol | DEY, INC. (F/K/A DEY LABORATORIES, INC.) | 2008-07-03 | — | — | US | disclosed |
| EP-1866323-A2 | GLUCURONIDATED NEBIVOLOL | MYLAN LABORATORIES, INC (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1848424-A2 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LABORATORIES, INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070014733-A1 | Hydroxylated nebivolol metabolites | DEY PHARMA, L.P. (F/K/A DEY L.P.) | 2007-01-18 | — | — | US | disclosed |
| US-20070014734-A1 | Glucuronidated nebivolol metabolites | MYLAN INC. (F/K/A MYLAN LABORATORIES INC.) | 2007-01-18 | — | — | US | disclosed |
| WO-2006083779-A2 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LABORATORIES, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006083780-A2 | GLUCURONIDATED NEBIVOLOL | MYLAN LABORATORIES, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161296-A1 | Compositions comprising nebivolol | ADRB1, ADRB3, ADRB2 | LMNA 185/4885NR1I2 554/4885PGR 3963/4885 |
| US-20070014734-A1 | Glucuronidated nebivolol metabolites | UGT1A4, UGT1A3, UGT1A1 | LMNA 1082/4885NR1I2 241/4885PGR 3024/4885 |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | EDNRB, EDNRA, ADRB1 | LMNA 862/4885NR1I2 967/4885PGR 4054/4885 |
| US-20070014733-A1 | Hydroxylated nebivolol metabolites | EDNRB, EDNRA, ADRB1 | LMNA 862/4885NR1I2 967/4885PGR 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.